Hospitals filled to capacity. Case counts climbing by the hour. Quarantine became routine. It was the beginning of the ...

New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑end manufacturing for all advanced ...

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

The pharmaceutical industry is far more complex than it appears, with different players handling everything from drug ...

NVO and PFE clash as the obesity market heats up, with shifting strategies, pipeline bets and growth pressures reshaping ...

Rather, industry experts told MD+DI that they expect injectable versions of GLP-1s for weight loss and diabetes will continue ...

Viatris, which Pfizer created in 2020, voluntarily withdrew extended-release products made at a plant in Ireland after an ...

Finding innovative ways to treat cancer is Pfizer’s biggest priority so to boost cutting-edge technologies, Pfizer executives went to Shenyang, China. There, last summer, Pfizer paid $1.25 billion to ...

Pfizer shared an update last week on its clinical trial for VALOR, which is short for "Vaccine Against Lyme for Outdoor Recreationists." The drugmaker said in its report that the vaccine was ...

Pfizer and Valenva are seeking regulatory approval from the Food and Drug Administration for a Lyme disease vaccine in development that's more than 70% effective against the tick-borne illness.

Pfizer (PFE) is trading at $26.59 with shares up 9.31% year-to-date, while Guggenheim raised its price target to $36 with a Buy rating versus Wall Street’s cautious $28.14 consensus. Pfizer’s oncology ...